Open AccessTherapeutic Targeting of Hypoxia-A2-Adenosinergic Pathway in COVID-19 Patients
Author(s) -
Katarina Halpin-Veszeleiova,
Stephen Hatfield
Publication year - 2022
Publication title -
physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.14
H-Index - 125
eISSN - 1548-9213
pISSN - 1548-9221
DOI - 10.1152/physiol.00010.2021
Subject(s) - adenosinergic , hypoxia (environmental) , immune system , immunology , biology , medicine , chemistry , oxygen , adenosine receptor , receptor , organic chemistry , agonist
The hypoxia-hypoxia-inducible factor (HIF)-1α-A2-adenosinergic pathway protects tissues from inflammatory damage during antipathogen immune responses. The elimination of this physiological tissue-protecting mechanism by supplemental oxygenation may contribute to the high mortality of oxygen-ventilated COVID-19 patients by exacerbating inflammatory lung damage. Restoration of this pathway with hypoxia-adenosinergic drugs may improve outcomes in these patients.